頁面
分類內容
Resources
- Package Insert - BioCode® SARS-CoV-2 Assay
- BioCode® STI + Resistance Panel
- Package Insert - BioCode® STI + Resistance Panel (RUO)
- 2023全年度財務報告書
- The Clinical Performance of the BioCode Respiratory Pathogen Panel for the Detection of Viruses and Bacteria from Nasopharyngeal Swabs, 2022
- Multicenter evaluation of BioCode GPP for syndromic molecular detection of gastrointestinal pathogens from stool specimens, 2024
- Evaluation of Chemagic 360 and KingFisher Flex Systems As Alternative Extraction Methods for the Applied BioCode FDA-cleared Respiratory Pathogen Panel (RPP) and MDx-3000 Molecular Diagnostic System, 2023
- 誠信經營守則
- 人權政策
- 112年度治理單位與會計師單獨會議議事錄
- 關係人交易管理作業辦法
- Performance Characterization of a Highly Multiplexed STI + Resistance Panel, 2023
- Evaluation of Chemagic 360 and KingFisher Flex Systems As Alternative Extraction Methods for the Applied BioCode FDA cleared 17-Plex Gastrointestinal Pathogen Panel (GPP) and MDx-3000 Molecular Diagnostic System, 2023
- Safety Data Sheet: BioCode CoV-2 Flu Plus Assay
- Safety Data Sheet: BioCode SARS-Cov-2 Assay
- Safety Data Sheet: BioCode Respiratory Pathogen Panel
- Safety Data Sheet: BioCode Gastrointestinal Pathogen Panel
- 2023第三季財務報告書
- Performance Characterization of a Highly Multiplexed RUO Fungal Pathogen Panel, 2023
- Evaluation of a Multiplex Endpoint PCR for the Detection of 22 Fungi Commonly Causing Fungal Pneumonia Using Barcoded Magnetic Bead Technology, 2023
- BioCode® SARS-CoV-2 Assay
- Package Insert - BioCode® CoV-2 Flu Plus Assay
- Package Insert - BioCode® Fungal Panel
- Package Insert - BioCode® Gastrointestinal Pathogen Panel
- Package Insert - BioCode® Respiratory Pathogen Panel
- 公司治理主管權責範圍與112年進修情形
- How to Improve Accessibility to Testing for GI Infections
- 2023第二季財務報告書
- 資通訊管理控制作業
- BioCode® MDx-3000
- 董事會資訊
- 公司大綱及章程
- 薪酬委員會組織規程
- 審計委員會組織規程
- 董事會議事規則
- 勞僱關係
- Development of a Syndromic Molecular Diagnostic Assay for Tick-Borne Pathogens Using Barcoded Magnetic Bead Technology
- 今年度持股比例占前十名之股東
- 2022股東常會年報
- Applied BioCode Corporation 2022 Annual Report
- 2023第一季財務報告書
- Consolidated Financial Statements and Independent Auditor’s Report 2022/2021
- Biocode Customer Application Note
- 2022全年度財務報告書
- 2022第三季財務報告書
- 2022第二季財務報告書
- 2022第一季財務報告書
- 2021第三季財務報告書
- 2021第二季財務報告書
- 2021第一季財務報告書
- 2020第三季財務報告書
- 2020第二季財務報告書
- 2020第一季財務報告書
- 2021全年度財務報告書
- 2020全年度財務報告書
- 2021股東常會年報
- 2020股東常會年報
- 公司治理實務守則
- 內部重大資訊處理暨防範內線交易管理作業
- 資通訊管理控制作業
- 內部稽核制度實施細則
- SDS BioCode® Cryptococcus spp. BMB-Probe
- CIO Insights Chris Bernard Cover Story
- SDS BioCode® Pneumocystis jirovecii BMB-Probe
- MDx-3000 Transforming your Lab Experience
- Evaluation of the Applied BioCode® Gastrointestinal Pathogen Panel, 2022
- The BioCode® 2500 Analyzer - System Overview
- User-Defined Mode - BioCode® MDx-3000
- BioCode® MDx-3000 System and Products Overview
- Evaluation of the GPP and RPP Panels at Cleveland Clinic
- Barcoded Magnetic Bead Technology
- Digital Barcodes Detect COVID-19 and 20 Pathogens
- Frequently Asked Questions
- Clinical and Analytical Evaluation of the Applied BioCode CoV-2 Flu Plus* Assay using MagNA Pure 96 and KingFisher Extraction Systems, 2022
- Cytokines & Chemokines Human, Mouse, Rat, Canine, & Monkey Product Information
- Multiplex Cytokine Immunoassay
- DNA Capture Probe BMB Coupling, Hybridization with Biotinylated Target, and SA-PE Reaction
- Package Insert - Nucleic Acid Coupling Kit
- Package Insert - Protein Coupling Kit
- BioCode® CoV-2 Flu Plus Assay kit
- Rules of Procedure for Shareholders Meetings
- Procedures for Ethical Management and Guidelines for Conduct
- Procedures for Election of Directors
- Management of Loans to Others
- Management of Endorsement and Guarantees
- Management of Board Meetings
- Management of Assets
- Ethical Corporate Management Best Practice Principles
- Corporate Social Responsibility Best Practice Principles
- Corporate Governance Best Practice Principles
- Codes of Ethical Conduct
- Audit Committee Charter
- Remuneration Committee Charter
- BioCode® Gastrointestinal Pathogen Panel
- BioCode® SARS-CoV-2 Assay kit
- Quality Management System - ISO 13485:2016 FM 661595
- Applied BioCode Corporation 2021 Annual Report
- Evaluation of a Flexible Molecular System for the Detection of Respiratory and Gastrointestinal Pathogens, 2022
- BioCode® MDx-3000 An Automated, High-Throughput Molecular Diagnostic System
- SDS-BioCoder-Pneumocystis-jirovecii-Primer-Pair
- BioCode® Analyte Specifc Reagents* (ASRs) for Fungal Pathogens
- BioCode® Respiratory Pathogen Panel
- SDS BioCode® Cunninghamella bertholletiae BMB-Probe
- SDS-BioCoder-Aspergillus-terreus-BMB-Probe
- SDS-BioCoder-Aspergillus-flavus-BMB-Probe
- SDS-BioCoder-Aspergillus-fumigatus-BMB-Probe
- SDS-BioCoder-Fusarium-oxysporum-BMB-Probe
- SDS-BioCoder-Aspergillus-niger-BMB-Probe
- SDS BioCode® DNA-IC Pack
- SDS BioCode® BMB Diluent
- SDS BioCode® Master Mix A
- SDS BioCode® Scedosporium prolificans BMB-Probe
- SDS BioCode® Scedosporium apiospermum BMB-Probe
- SDS BioCode® Rhizopus spp. BMB-Probe
- SDS BioCode® Rhizopus oryzae BMB-Probe
- SDS BioCode® Rhizopus microsporus BMB-Probe
- SDS BioCode® Rhizomucor spp. BMB-Probe
- SDS BioCode® Mucor indicus BMB-Probe
- SDS BioCode® Fusarium solani BMB-Probe
- Consolidated Financial Statements and Independent Auditor’s Report 2021/2020
- BioCode® CoV-2 Flu Plus Assay - EUA Authorization Letter, December 16, 2021
- BioCode® CoV-2 Flu Plus Assay - Fact Sheet for Healthcare Providers
- BioCode® CoV-2 Flu Plus Assay - Fact Sheet for Patients
- BioCode® CoV-2 Assay - "Detects Omicron and Other COVID Variants" Letter, December 6, 2021
- BioCode® Histoplasma capsulatum BMB-Probe
- BioCode® Coccidioides spp. BMB-Probe
- BioCode® Candida tropicalis BMB-Probe
- BioCode® Candida parapsilosis BMB-Probe
- BioCode® Candida lusitaniae BMB-Probe
- BioCode® Candida krusei BMB-Probe
- BioCode® Candida guilliermondii BMB-Probe
- BioCode® Candida glabrata BMB-Probe
- BioCode® Candida dubliniensis BMB-Probe
- BioCode® Candida auris BMB-Probe
- BioCode® Candida albicans BMB-Probe
- BioCode® Blastomyces dermatitidis BMB-Probe
- BioCode® Fungal ITS2 Primer Pair
- BioCode® 2500 - Multiplex MDx and Immunoassay Reader
- SDS - BioCode SA-PE Mix Pack
- BioCode® SARS-CoV-2 Assay Kit - Fact Sheet for Healthcare Providers
- BioCode® SARS-CoV-2 Assay Kit - Fact Sheet for Patients
- Applied BioCode Corporation 2020 Annual Report
- BioCode® CoV-2 Assay - "Pooled Sampling" EUA Authorization Letter, December 7, 2020
- Consolidated Financial Statements and Independent Auditor's Report 2020/2019
- BioCode® CoV-2 Assay - EUA Authorization Letter, June 15, 2020
- Clinical Assessment of the Applied BioCode Respiratory Pathogen Panel, 2019
- Validation and Performance of PCR/ Sequencing Assays for Upper Respiratory Pathogens, 2019
- Performance Characterization of a Respiratory Pathogen Panel with an Automated High-Throughput System, 2019
- Barcoded Magnetic Bead Technology
- MSDS - 4096-plex P-Carboxyl BMB
- MSDS - 4096-plex Amino BMB
- MSDS - 4096-plex Carboxyl BMB
- MSDS - BioCode® MDx-3000 Calibration Kit
- Beta Site Evaluation of an 18-Plex Gastrointestinal Pathogen Panel With an Automated, High Throughput System, 2018
- Development and Characterization of a Respiratory Pathogen Panel with an Automated High-Throughput System, 2018
- MSDS - 4096-plex Standard BMB
- MSDS - Detection Buffer with Antifoam
- MSDS - 4096-plex Streptavidin BMB
- MSDS - BioCode® 2500 Calibration Kit
- MSDS: BioCode MDx 3000 Buffer A
- Evaluation Of MagNA Pure 96 As Alternative Extraction Method for the BioCode® Gastrointestinal Pathogen Panel, 2018
- Development of a Respiratory Pathogen Panel with an Automated High Throughput System - BioCode MDx-3000, 2017
- Validation and Performance of Sequencing-Based Reference Assays for BioCode GI Panel, 2017
- Performance Evaluation of an 18-Plex Molecular Gastrointestinal Pathogen Panel with an Automated, High-Throughput System, 2017
- Reproducibility and Front-End Extraction Compatability for an 18-Plex Gastrointestinal Pathogen Panel with an Automated, High-Throughput System, 2017
- Characterization of an 18 target Molecular Gastrointestinal Pathogen Panel with High Throughput BioCode MDx 3000 System, 2016
- Multiplex Molecular Gastrointestinal Pathogen Detection with an Automated Throughput System, 2016
- Advances in multiplex nucleic acid diagnostics for blood-borne pathogens: promises and pitfalls. Expert Review of Molecular Diagnositcs. Early online, 1-13 (2015)
- Development of a Rapid Multiplex Molecular Assay for the Detection of Bacteria from Necrotic Wounds, 2015
- Validation of Methods Producing Spiked Blood and Plasma Samples for Use to Evaluate Analytical Sensitivity and Reproducibility for Rare Pathogens, 2015
- Multiplex Molecular Gastrointestinal Pathogen Detection with an Automated, High Throughput System, 2015
- A User-Friendly Automated System Evaluated With A Multiplex GI Panel Pathogen Detection, 2015
- Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther. 2015;42:71-83 (2015).
- MSDS - 128-plex Carboxyl BMB
- BioCode MDx 3000 For Multiplex GI Pathogen Detection, 2014
- GenomeWeb News--Applied BioCode Developing Multiplex, Bead-Based GI Pathogen Detection Panel (2014)
- SNP Assay Multiplexing Using Barcoded Magnetic Beads in Array Tape™ - Douglas Scientific, LLC (2013)
- Evaluation of the EraGen MultiCode-Plx Respiratory Virus Panel using Barcoded Magnetic Beads designed to Detect Seventeen Respiratory Viruses - Presented at the Clinical Virology Symposium (2011)
- AACC Oak Ridge Conference 2010: Cytokine Panel
- Clinical Virology Symposium (CVS) 2010: Respiratory Virus Panel
Testimonials
Resource Categories
Categories
